<DOC>
	<DOCNO>NCT02606084</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics single dose intranasally administer esketamine participant impair renal function compare participant normal renal function .</brief_summary>
	<brief_title>A Study Assess Effects Renal Impairment Pharmacokinetics , Safety , Tolerability Intranasally Administered Esketamine</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , single-dose , single-center , parallel group study characterize pharmacokinetics safety single 28 milligram ( mg ) dose esketamine participant vary stage renal impairment healthy participant . A total approximately 32 medically stable men woman vary degree renal function impairment renal impairment enrol . The study consist Screening period Days -21 -2 , open label phase Days -1 4 , end-of-study ( 11 plus [ + ] minus [ - ] 2 day final dose ) . The participant assign 1 4 group ( 8 participant per group ) base creatinine clearance ( CLCR , ) . Safety tolerability assess time consent end study .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Signed informed consent document indicate understand purpose procedure require study willing participate study For woman childbearing potential , must negative serum betahuman chorionic gonadotropin ( betahCG ) pregnancy test Screening ; negative urine pregnancy test Day minus ( ) 1 Comfortable selfadministration intranasal medication able follow instruction provide Hemoglobin concentration great equal ( &gt; = ) 10 gram per deciLiter ( g/dL ) ( Only cohorts 1 , 2 , 3 ) Platelet count &gt; = 50,000 counts/microliter ( Only cohorts 1 , 2 , 3 ) Current previous diagnosis psychotic major depressive disorder ( MDD ) psychosis , bipolar relate disorder , intellectual disability , borderline personality disorder , antisocial personality disorder A lifetime history cerebrovascular disease include stroke transient ischemic attack , aneurysmal vascular disease Unstable coronary artery disease myocardial infarction last 12 month unstable angina require revascularization procedure , hemodynamically significant valvular heart disease , New York Heart Association Class IIIIV heart failure Has renal transplant diagnosis systemic lupus erythromatosus renal carcinoma Has nasal pierce Participant require dialysis ( Only cohorts 1 , 2 , 3 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Renal Impairment</keyword>
	<keyword>Healthy</keyword>
	<keyword>Esketamine</keyword>
</DOC>